Table 1. Patients’ characteristics and results obtained with cetuximab.

Total number	4
Age (years)
Median (minimum–maximum)	64.25 (57–61)
Gender, number (%)
Male	3 (75)
Female	1 (25)
Primary site (%)
Duodenum	2 (50)
Jejunum	2 (50)
Grading, number (%)
Well differentiated	0 (0)
Moderately differentiated	1 (25)
Poorly differentiated	2 (50)
KRas status
Wild-type	3 (75%)
Mutant	0 (0%)
Not available	1 (25%)
Response to cetuximab
Progression	0 (0%)
Stable disease (second line)	1 (25%)
Partial response (first and second line)	2 (50%)
Complete response (first line)	1 (25%)
Skin rash
G0	1 (25%)
G1	0 (0%)
G2	3 (75%)